Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Operating Leases (2019 - 2025)

Tg Therapeutics (TGTX) has 7 years of Operating Leases data on record, last reported at $7.0 million in Q4 2025.

  • For Q4 2025, Operating Leases fell 13.67% year-over-year to $7.0 million; the TTM value through Dec 2025 reached $7.0 million, down 13.67%, while the annual FY2025 figure was $7.0 million, 13.67% down from the prior year.
  • Operating Leases reached $7.0 million in Q4 2025 per TGTX's latest filing, down from $7.3 million in the prior quarter.
  • Across five years, Operating Leases topped out at $10.6 million in Q3 2022 and bottomed at $7.0 million in Q4 2025.
  • Average Operating Leases over 5 years is $9.2 million, with a median of $9.7 million recorded in 2023.
  • Peak YoY movement for Operating Leases: increased 5.61% in 2022, then dropped 13.67% in 2025.
  • A 5-year view of Operating Leases shows it stood at $9.8 million in 2021, then rose by 5.05% to $10.3 million in 2022, then dropped by 10.76% to $9.2 million in 2023, then dropped by 11.89% to $8.1 million in 2024, then dropped by 13.67% to $7.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $7.0 million in Q4 2025, $7.3 million in Q3 2025, and $7.6 million in Q2 2025.